New hope for ALS: experimental drug dazucorilant enters phase 2 trial
NCT ID NCT05407324
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 11 times
Summary
This study tests whether a new drug called dazucorilant can slow down ALS and improve muscle strength and breathing. About 279 adults with ALS will receive either the drug or a placebo for 24 weeks. The goal is to see if the drug is safe and helps people maintain their daily function longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
062
RECRUITINGPhoenix, Arizona, 85013, United States
-
108
ACTIVE_NOT_RECRUITINGLeuven, 3000, Belgium
-
115
ACTIVE_NOT_RECRUITINGBarcelona, 08035, Spain
-
194
ACTIVE_NOT_RECRUITINGValencia, 46026, Spain
-
253
ACTIVE_NOT_RECRUITINGDublin, D09 YD60, Ireland
-
254
ACTIVE_NOT_RECRUITINGWarsaw, 01-684, Poland
-
255
ACTIVE_NOT_RECRUITINGBerlin, 13353, Germany
-
256
ACTIVE_NOT_RECRUITINGTours, 37000, France
-
257
ACTIVE_NOT_RECRUITINGLimoges, 87042, France
-
258
ACTIVE_NOT_RECRUITINGLille, 59037, France
-
259
ACTIVE_NOT_RECRUITINGNice, 06001, France
-
260
ACTIVE_NOT_RECRUITINGHanover, 30625, Germany
-
261
ACTIVE_NOT_RECRUITINGMarseille, 13385, France
-
262
ACTIVE_NOT_RECRUITINGParis, 75651, France
-
263
ACTIVE_NOT_RECRUITINGStoke-on-Trent, ST4 6QG, United Kingdom
-
264
ACTIVE_NOT_RECRUITINGUtrecht, 3584 CW, Netherlands
-
265
ACTIVE_NOT_RECRUITINGJena, 7747, Germany
-
267
ACTIVE_NOT_RECRUITINGRostock, 18147, Germany
-
268
ACTIVE_NOT_RECRUITINGDresden, 1307, Germany
-
269
ACTIVE_NOT_RECRUITINGUlm, 89081, Germany
-
270
ACTIVE_NOT_RECRUITINGBonn, 53127, Germany
-
273
ACTIVE_NOT_RECRUITINGMontreal, Quebec, H3A2B4, Canada
-
274
ACTIVE_NOT_RECRUITINGWarsaw, 02-473, Poland
-
278
RECRUITINGSan Francisco, California, 94109, United States
-
282
ACTIVE_NOT_RECRUITINGMálaga, 29010, Spain
-
283
ACTIVE_NOT_RECRUITINGBydgoszcz, 85-163, Poland
-
287
RECRUITINGNeptune City, New Jersey, 07753, United States
-
302
ACTIVE_NOT_RECRUITINGBarcelona, 08003, Spain
-
303
ACTIVE_NOT_RECRUITINGMadrid, 28046, Spain
-
353
RECRUITINGNew York, New York, 10032, United States
-
385
ACTIVE_NOT_RECRUITINGKrakow, 30721, Poland
-
386
ACTIVE_NOT_RECRUITINGMünchen, 81675, Germany
-
422
ACTIVE_NOT_RECRUITINGBron, 69500, France
-
423
ACTIVE_NOT_RECRUITINGMontpellier, 42395, France
-
425
ACTIVE_NOT_RECRUITINGHamilton, Ontario, L8N 3Z5, Canada
Conditions
Explore the condition pages connected to this study.